COSCIENS Biopharma Inc. Appoints New CEO Anna Biehn to Lead Next Growth Phase
Company - People | Apr 14, 2025 | EIN
COSCIENS Biopharma Inc., a company listed on Nasdaq and the Toronto Stock Exchange, has announced the appointment of Anna Biehn as its new CEO effective May 5, 2025. Biehn, who has over 25 years of global management and marketing experience, joins from NuTek Natural Ingredients, where she served as CFO. The appointment marks a strategic move for COSCIENS, which seeks to leverage Biehn’s expertise in consumer insights and commercialization to propel its portfolio of natural, health-focused products. Former CEO Gilles Gagnon will stay on as a Strategic Advisor to ensure a seamless transition and contribute to the company's continued growth. COSCIENS, the product of a merger between Aeterna Zentaris and Ceapro Inc., focuses on cosmeceuticals, nutraceuticals, and pharmaceuticals, using proprietary extraction technology to develop active ingredients from renewable plants. The company is eyeing substantial growth opportunities in the expanding natural health products sector.
Sectors
- Biopharmaceuticals
- Consumer Products
- Natural Ingredients
Geography
- United States – COSCIENS Biopharma Inc. is listed on NASDAQ, an American stock exchange.
- Canada – COSCIENS Biopharma Inc. is also listed on the Toronto Stock Exchange and results from the merger of Canadian firms Aeterna Zentaris and Ceapro Inc.
Industry
- Biopharmaceuticals – COSCIENS is involved in developing biopharmaceutical products, focusing on health and wellness.
- Consumer Products – The company’s portfolio includes consumer-focused products, such as cosmeceuticals and nutraceuticals.
- Natural Ingredients – The focus on natural-based product development and commercializing products derived from plant-based resources highlights this classification.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| COSCIENS Biopharma Inc. | Target Company | Company | A biopharmaceutical company focused on developing and commercializing natural-based products. |
| Anna Biehn | Appointed CEO | Person | Appointed CEO of COSCIENS Biopharma to drive the company's next growth phase. |
| Gilles Gagnon | Outgoing CEO and Strategic Advisor | Person | Outgoing CEO who will remain as a Strategic Advisor to ensure a smooth transition. |
| NuTek Natural Ingredients | Former Employer of New CEO | Company | Former company where Anna Biehn served as Chief Financial Officer. |